サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1606341

急性興奮および攻撃性治療市場；-世界の産業分析、規模、シェア、成長、動向、予測、2024～2034年

Acute Agitation and Aggression Treatment Market; - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 213 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
急性興奮および攻撃性治療市場；-世界の産業分析、規模、シェア、成長、動向、予測、2024～2034年
出版日: 2024年10月15日
発行: Transparency Market Research
ページ情報: 英文 213 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

急性興奮および攻撃性治療市場- 調査範囲

TMRの調査レポート「急性興奮および攻撃性治療の世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の急性興奮および攻撃性治療市場の収益と予測を提供しています。また、2024年から2034年までの世界の急性興奮および攻撃性治療市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、急性興奮および攻撃性治療市場を推察しました。

市場スナップショット
2023年の市場規模 50億米ドル
2034年の市場規模 82億米ドル
CAGR 4.6%

本レポートでは、世界の急性興奮および攻撃性治療市場の競合情勢について掘り下げています。世界の急性興奮および攻撃性治療市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介している世界の急性興奮および攻撃性治療市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の市場分析と予測、2020年～2034年

第5章 主要洞察

  • 治療プロトコル
  • 採用された主要戦略市場企業
  • 国別のメンタルヘルス支出
  • ヘルスケア業界の概要
  • PESTEL分析
  • ポーターのファイブフォース分析
  • パイプライン分析
  • 規制シナリオ評価
  • 主要国別の償還シナリオ
  • 急性興奮および攻撃性障害の疫学
  • サプライチェーン分析
  • 主要な業界イベント

第6章 世界の市場分析と予測：治療アプローチ別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：治療アプローチ別、2020年～2034年
    • 第一世代の抗精神病薬：
      • クロルプロマジン
      • ハロペリドール
    • 第二世代の抗精神病薬：
      • クエチアピン
      • オランザピン
      • ジプラシドン
    • ベンゾジアゼピン
      • ロラゼパム
      • ミダゾラム
    • アルファ2アドレナリン作動薬
      • クロニジン
      • デクスメデトミジン
    • その他
  • 市場の魅力分析：治療アプローチ別

第7章 世界の市場分析と予測：適応症別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：適応症別、2020年～2034年
    • アルコール離脱
    • 双極性障害
    • 痴呆
    • うつ
    • 薬物による興奮と攻撃性
    • 統合失調症
    • その他
  • 市場の魅力分析：適応症別

第8章 世界の市場分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：流通チャネル別、2020年～2034年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場の魅力分析：流通チャネル別

第9章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2020年～2034年
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域別

第10章 北米の市場分析と予測

第11章 欧州の市場分析と予測

第12章 アジア太平洋地域の市場分析と予測

第13章 ラテンアメリカの市場分析と予測

第14章 中東・アフリカの市場分析と予測

第15章 競合情勢

  • 市場企業-競合マトリックス（企業階層と規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • Eli Lilly and Company
    • Pfizer, Inc.
    • GlaxoSmithKline
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd.
    • Amneal Pharmaceuticals LLC
    • F. Hoffmann-La Roche Ltd
    • Bausch Health Companies, Inc.
    • Apotex, Inc.
図表

List of Tables

  • Table 01: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Treatment Approach, 2020-2034
  • Table 02: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by First-Generation Anti-Psychotics, 2020-2034
  • Table 03: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Second-Generation Anti-Psychotics, 2020-2034
  • Table 04: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Benzodiazepines, 2020-2034
  • Table 05: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Alpha-2 Adrenergic Agonist, 2020-2034
  • Table 06: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 07: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 08: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Region, 2020-2034
  • Table 09: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 10: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Treatment Approach, 2020-2034
  • Table 11: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by First-Generation Anti-Psychotics, 2020-2034
  • Table 12: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Second-Generation Anti-Psychotics, 2020-2034
  • Table 13: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Benzodiazepines, 2020-2034
  • Table 14: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Alpha-2 Adrenergic Agonist, 2020-2034
  • Table 15: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 16: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 17: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Treatment Approach, 2020-2034
  • Table 19: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by First-Generation Anti-Psychotics, 2020-2034
  • Table 20: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Second-Generation Anti-Psychotics, 2020-2034
  • Table 21: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Benzodiazepines, 2020-2034
  • Table 22: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Alpha-2 Adrenergic Agonist, 2020-2034
  • Table 23: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 24: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 25: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 26: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Treatment Approach, 2020-2034
  • Table 27: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by First-Generation Anti-Psychotics, 2020-2034
  • Table 28: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Second-Generation Anti-Psychotics, 2020-2034
  • Table 29: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Benzodiazepines, 2020-2034
  • Table 30: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Alpha-2 Adrenergic Agonist, 2020-2034
  • Table 31: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 32: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 33: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 34: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Treatment Approach, 2020-2034
  • Table 35: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by First-Generation Anti-Psychotics, 2020-2034
  • Table 36: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Second-Generation Anti-Psychotics, 2020-2034
  • Table 37: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Benzodiazepines, 2020-2034
  • Table 38: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Alpha-2 Adrenergic Agonist, 2020-2034
  • Table 39: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 40: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 41: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 42: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Treatment Approach, 2020-2034
  • Table 43: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by First-Generation Anti-Psychotics, 2020-2034
  • Table 44: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Second-Generation Anti-Psychotics, 2020-2034
  • Table 45: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Benzodiazepines, 2020-2034
  • Table 46: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Alpha-2 Adrenergic Agonist, 2020-2034
  • Table 47: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 48: Middle East and Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 02: Global Acute Agitation and Aggression Treatment Market Value Share, by Treatment Approach, 2023
  • Figure 03: Global Acute Agitation and Aggression Treatment Market Value Share, by Indication, 2023
  • Figure 04: Global Acute Agitation and Aggression Treatment Market Value Share, by Distribution Channel, 2023
  • Figure 05: Global Acute Agitation and Aggression Treatment Market Value Share, by Region, 2023
  • Figure 06: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Share Analysis, by Treatment Approach, 2023 and 2034
  • Figure 07: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Treatment Approach, 2023
  • Figure 08: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Treatment Approach, 2034
  • Figure 09: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2024-2034
  • Figure 10: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by First-Generation Anti-Psychotics, 2020-2034
  • Figure 11: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by First-Generation Anti-Psychotics, 2024 and 2034
  • Figure 12: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Second-Generation Anti-Psychotics, 2020-2034
  • Figure 13: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Second-Generation Anti-Psychotics, 2024 and 2034
  • Figure 14: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Benzodiazepines, 2020-2034
  • Figure 15: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Benzodiazepines, 2024 and 2034
  • Figure 16: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Alpha-2 Adrenergic Agonist, 2020-2034
  • Figure 17: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Alpha-2 Adrenergic Agonist, 2024 and 2034
  • Figure 18: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Others, 2020-2034
  • Figure 19: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Others, 2024 and 2034
  • Figure 20: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Share Analysis, by Indication, 2023 and 2034
  • Figure 21: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Indication, 2023
  • Figure 22: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Indication, 2034
  • Figure 23: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 24: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Alcohol Withdrawal, 2020-2034
  • Figure 25: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Alcohol Withdrawal, 2024 and 2034
  • Figure 26: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Bipolar Disorder, 2020-2034
  • Figure 27: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Bipolar Disorder, 2024 and 2034
  • Figure 28: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Dementia, 2020-2034
  • Figure 29: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Dementia, 2024 and 2034
  • Figure 30: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Depression, 2020-2034
  • Figure 31: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Depression, 2024 and 2034
  • Figure 32: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Drug-induced agitation and aggression, 2020-2034
  • Figure 33: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Drug-induced agitation and aggression, 2024 and 2034
  • Figure 34: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Schizophrenia, 2020-2034
  • Figure 35: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Schizophrenia, 2024 and 2034
  • Figure 36: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Others, 2020-2034
  • Figure 37: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Others, 2024 and 2034
  • Figure 38: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 39: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Distribution Channel, 2023
  • Figure 40: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Distribution Channel, 2034
  • Figure 41: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 42: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Hospital Pharmacies, 2020-2034
  • Figure 43: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Hospital Pharmacies, 2024 and 2034
  • Figure 44: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Retail Pharmacies, 2020-2034
  • Figure 45: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Retail Pharmacies, 2024 and 2034
  • Figure 46: Global Acute Agitation and Aggression Treatment Market Value (US$ Bn), by Online Pharmacies, 2020-2034
  • Figure 47: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Online Pharmacies, 2024 and 2034
  • Figure 48: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 49: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Region, 2023
  • Figure 50: Global Acute Agitation and Aggression Treatment Market Share Analysis, by Region, 2034
  • Figure 51: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: North America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 53: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 54: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 55: North America Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Treatment Approach, 2023 and 2034
  • Figure 56: North America Acute Agitation and Aggression Treatment Attractiveness Analysis, by Treatment Approach, 2024-2034
  • Figure 57: North America Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Indication, 2023 and 2034
  • Figure 58: North America Acute Agitation and Aggression Treatment Attractiveness Analysis, by Indication, 2024-2034
  • Figure 59: North America Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 60: North America Acute Agitation and Aggression Treatment Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 61: Europe Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 62: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 63: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 64: Europe Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Treatment Approach, 2023 and 2034
  • Figure 65: Europe Acute Agitation and Aggression Treatment Attractiveness Analysis, by Treatment Approach, 2024-2034
  • Figure 66: Europe Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Indication, 2023 and 2034
  • Figure 67: Europe Acute Agitation and Aggression Treatment Attractiveness Analysis, by Indication, 2024-2034
  • Figure 68: Europe Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 69: Europe Acute Agitation and Aggression Treatment Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 70: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 71: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 72: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 73: Asia Pacific Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Treatment Approach, 2023 and 2034
  • Figure 74: Asia Pacific Acute Agitation and Aggression Treatment Attractiveness Analysis, by Treatment Approach, 2024-2034
  • Figure 75: Asia Pacific Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Indication, 2023 and 2034
  • Figure 76: Asia Pacific Acute Agitation and Aggression Treatment Attractiveness Analysis, by Indication, 2024-2034
  • Figure 77: Asia Pacific Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 78: Asia Pacific Acute Agitation and Aggression Treatment Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 79: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 80: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 81: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 82: North America Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Treatment Approach, 2023 and 2034
  • Figure 83: North America Acute Agitation and Aggression Treatment Attractiveness Analysis, by Treatment Approach, 2024-2034
  • Figure 84: Latin America Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Indication, 2023 and 2034
  • Figure 85: Latin America Acute Agitation and Aggression Treatment Attractiveness Analysis, by Indication, 2024-2034
  • Figure 86: Latin America Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 87: Latin America Acute Agitation and Aggression Treatment Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 88: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 89: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 90: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 91: Middle East and Africa Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Treatment Approach, 2023 and 2034
  • Figure 92: Middle East and Africa Acute Agitation and Aggression Treatment Attractiveness Analysis, by Treatment Approach, 2024-2034
  • Figure 93: Middle East and Africa Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Indication, 2023 and 2034
  • Figure 94: Middle East and Africa Acute Agitation and Aggression Treatment Attractiveness Analysis, by Indication, 2024-2034
  • Figure 95: Middle East and Africa Acute Agitation and Aggression Treatment Value (US$ Bn) Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 96: Middle East and Africa Acute Agitation and Aggression Treatment Attractiveness Analysis, by Distribution Channel, 2024-2034
目次
Product Code: TMRGL72345

Acute Agitation and Aggression Treatment Market - Scope of Report

TMR's report on the global acute agitation and aggression treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global acute agitation and aggression treatment market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute agitation and aggression treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the acute agitation and aggression treatment market.

Market Snapshot
Market Value in 2023US$ 5 Bn
Market Value in 2034US$ 8.2 Bn
CAGR4.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global acute agitation and aggression treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global acute agitation and aggression treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global acute agitation and aggression treatment market.

The report delves into the competitive landscape of the global acute agitation and aggression treatment market. Key players operating in the global acute agitation and aggression treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global acute agitation and aggression treatment market profiled in this report.

Key Questions Answered in Global acute agitation and aggression treatment Market Report:

  • What is the sales/revenue generated by acute agitation and aggression treatment across all regions during the forecast period?
  • What are the opportunities in the global acute agitation and aggression treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Acute Agitation and Aggression Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global acute agitation and aggression treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global acute agitation and aggression treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global acute agitation and aggression treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Acute Agitation and Aggression Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, 2020-2034
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Treatment Protocol
  • 5.2. Key Strategies adopted by Market Players
  • 5.3. Mental Health Spendings by Countries
  • 5.4. Healthcare Industry Overview
  • 5.5. PESTEL Analysis
  • 5.6. PORTER's Five Forces Analysis
  • 5.7. Pipeline Analysis
  • 5.8. Regulatory Scenario Assessment
  • 5.9. Reimbursement Scenario by Key Countries
  • 5.10. Epidemiology of Acute Agitations and Aggression Disorders
  • 5.11. Supply Chain Analysis
  • 5.12. Key Industry Events

6. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Treatment Approach

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Approach, 2020-2034
    • 6.3.1. First-Generation Anti-Psychotics:
      • 6.3.1.1. Chlorpromazine
      • 6.3.1.2. Haloperidol
    • 6.3.2. Second-Generation Anti-Psychotics
      • 6.3.2.1. Quetiapine
      • 6.3.2.2. Olanzapine
      • 6.3.2.3. Ziprasidone
    • 6.3.3. Benzodiazepines
      • 6.3.3.1. Lorazepam
      • 6.3.3.2. Midazolam
    • 6.3.4. Alpha-2 Adrenergic Agonist
      • 6.3.4.1. Clonidine
      • 6.3.4.2. Dexmedetomidine
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Treatment Approach

7. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Indication, 2020-2034
    • 7.3.1. Alcohol Withdrawal
    • 7.3.2. Bipolar Disorder
    • 7.3.3. Dementia
    • 7.3.4. Depression
    • 7.3.5. Drug-induced agitation and aggression
    • 7.3.6. Schizophrenia
    • 7.3.7. Others
  • 7.4. Market Attractiveness Analysis, by Indication

8. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Acute Agitation and Aggression Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Treatment Approach, 2020-2034
    • 10.2.1. First-Generation Anti-Psychotics:
      • 10.2.1.1. Chlorpromazine
      • 10.2.1.2. Haloperidol
    • 10.2.2. Second-Generation Anti-Psychotics
      • 10.2.2.1. Quetiapine
      • 10.2.2.2. Olanzapine
      • 10.2.2.3. Ziprasidone
    • 10.2.3. Benzodiazepines
      • 10.2.3.1. Lorazepam
      • 10.2.3.2. Midazolam
    • 10.2.4. Alpha-2 Adrenergic Agonist
      • 10.2.4.1. Clonidine
      • 10.2.4.2. Dexmedetomidine
    • 10.2.5. Others
  • 10.3. Market Value Forecast, by Indication, 2020-2034
    • 10.3.1. Alcohol Withdrawal
    • 10.3.2. Bipolar Disorder
    • 10.3.3. Dementia
    • 10.3.4. Depression
    • 10.3.5. Drug-induced agitation and aggression
    • 10.3.6. Schizophrenia
    • 10.3.7. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2020-2034
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Treatment Approach
    • 10.6.2. By Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Acute Agitation and Aggression Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment Approach, 2020-2034
    • 11.2.1. First-Generation Anti-Psychotics:
      • 11.2.1.1. Chlorpromazine
      • 11.2.1.2. Haloperidol
    • 11.2.2. Second-Generation Anti-Psychotics
      • 11.2.2.1. Quetiapine
      • 11.2.2.2. Olanzapine
      • 11.2.2.3. Ziprasidone
    • 11.2.3. Benzodiazepines
      • 11.2.3.1. Lorazepam
      • 11.2.3.2. Midazolam
    • 11.2.4. Alpha-2 Adrenergic Agonist
      • 11.2.4.1. Clonidine
      • 11.2.4.2. Dexmedetomidine
    • 11.2.5. Others
  • 11.3. Market Value Forecast, by Indication, 2020-2034
    • 11.3.1. Alcohol Withdrawal
    • 11.3.2. Bipolar Disorder
    • 11.3.3. Dementia
    • 11.3.4. Depression
    • 11.3.5. Drug-induced agitation and aggression
    • 11.3.6. Schizophrenia
    • 11.3.7. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.5.1. Germany
    • 11.5.2. UK
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Treatment Approach
    • 11.6.2. By Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Acute Agitation and Aggression Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment Approach, 2020-2034
    • 12.2.1. First-Generation Anti-Psychotics:
      • 12.2.1.1. Chlorpromazine
      • 12.2.1.2. Haloperidol
    • 12.2.2. Second-Generation Anti-Psychotics
      • 12.2.2.1. Quetiapine
      • 12.2.2.2. Olanzapine
      • 12.2.2.3. Ziprasidone
    • 12.2.3. Benzodiazepines
      • 12.2.3.1. Lorazepam
      • 12.2.3.2. Midazolam
    • 12.2.4. Alpha-2 Adrenergic Agonist
      • 12.2.4.1. Clonidine
      • 12.2.4.2. Dexmedetomidine
      • 12.2.4.3. Guanabenz
    • 12.2.5. Others
  • 12.3. Market Value Forecast, by Indication, 2020-2034
    • 12.3.1. Alcohol Withdrawal
    • 12.3.2. Bipolar Disorder
    • 12.3.3. Dementia
    • 12.3.4. Depression
    • 12.3.5. Drug-induced agitation and aggression
    • 12.3.6. Schizophrenia
    • 12.3.7. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & Newzealend
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Treatment Approach
    • 12.6.2. By Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Acute Agitation and Aggression Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment Approach, 2020-2034
    • 13.2.1. First-Generation Anti-Psychotics:
      • 13.2.1.1. Chlorpromazine
      • 13.2.1.2. Haloperidol
    • 13.2.2. Second-Generation Anti-Psychotics
      • 13.2.2.1. Quetiapine
      • 13.2.2.2. Olanzapine
      • 13.2.2.3. Ziprasidone
    • 13.2.3. Benzodiazepines
      • 13.2.3.1. Lorazepam
      • 13.2.3.2. Midazolam
    • 13.2.4. Alpha-2 Adrenergic Agonist
      • 13.2.4.1. Clonidine
      • 13.2.4.2. Dexmedetomidine
      • 13.2.4.3. Guanabenz
    • 13.2.5. Others
  • 13.3. Market Value Forecast, by Indication, 2020-2034
    • 13.3.1. Alcohol Withdrawal
    • 13.3.2. Bipolar Disorder
    • 13.3.3. Dementia
    • 13.3.4. Depression
    • 13.3.5. Drug-induced agitation and aggression
    • 13.3.6. Schizophrenia
    • 13.3.7. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Treatment Approach
    • 13.6.2. By Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Acute Agitation and Aggression Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Treatment Approach, 2020-2034
    • 14.2.1. First-Generation Anti-Psychotics:
      • 14.2.1.1. Chlorpromazine
      • 14.2.1.2. Haloperidol
    • 14.2.2. Second-Generation Anti-Psychotics
      • 14.2.2.1. Quetiapine
      • 14.2.2.2. Olanzapine
      • 14.2.2.3. Ziprasidone
    • 14.2.3. Benzodiazepines
      • 14.2.3.1. Lorazepam
      • 14.2.3.2. Midazolam
    • 14.2.4. Alpha-2 Adrenergic Agonist
      • 14.2.4.1. Clonidine
      • 14.2.4.2. Dexmedetomidine
      • 14.2.4.3. Guanabenz
    • 14.2.5. Others
  • 14.3. Market Value Forecast, by Indication, 2020-2034
    • 14.3.1. Alcohol Withdrawal
    • 14.3.2. Bipolar Disorder
    • 14.3.3. Dementia
    • 14.3.4. Depression
    • 14.3.5. Drug-induced agitation and aggression
    • 14.3.6. Schizophrenia
    • 14.3.7. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Treatment Approach
    • 14.6.2. By Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Eli Lilly and Company
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Pfizer, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. GlaxoSmithKline
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. Johnson & Johnson
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Teva Pharmaceutical Industries Ltd.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Amneal Pharmaceuticals LLC
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. F. Hoffmann-La Roche Ltd
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. Bausch Health Companies, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. Apotex, Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments